| pubmed-article:20643531 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C1565860 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C1705323 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0014556 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0023175 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0879626 | lld:lifeskim |
| pubmed-article:20643531 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:20643531 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:20643531 | pubmed:dateCreated | 2010-8-27 | lld:pubmed |
| pubmed-article:20643531 | pubmed:abstractText | Status epilepticus (SE) leads to upregulation of pro-inflammatory proteins including cyclooxygenase-2 (cox-2) which could be implicated in the epileptogenic process and epileptic seizures. Recent studies show that cox-2 can regulate expression of P-glycoprotein (P-gp) during epileptogenesis and epilepsy. P-gp could cause pharmacoresistance by reducing brain entry of anti-epileptic drugs such as phenytoin (PHT). Here we have investigated the effects of cox-2 inhibition on epileptogenesis, spontaneous seizures and PHT treatment in a rat model for temporal lobe epilepsy (TLE). | lld:pubmed |
| pubmed-article:20643531 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20643531 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20643531 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20643531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20643531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20643531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20643531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20643531 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20643531 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20643531 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:20643531 | pubmed:issn | 1872-6844 | lld:pubmed |
| pubmed-article:20643531 | pubmed:author | pubmed-author:GorterJan AJA | lld:pubmed |
| pubmed-article:20643531 | pubmed:author | pubmed-author:AronicaEleono... | lld:pubmed |
| pubmed-article:20643531 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:20643531 | pubmed:author | pubmed-author:EdelbroekPete... | lld:pubmed |
| pubmed-article:20643531 | pubmed:author | pubmed-author:HoltmanLindaL | lld:pubmed |
| pubmed-article:20643531 | pubmed:copyrightInfo | Copyright 2010 Elsevier B.V. All rights reserved. | lld:pubmed |
| pubmed-article:20643531 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20643531 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:20643531 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20643531 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20643531 | pubmed:pagination | 49-56 | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:meshHeading | pubmed-meshheading:20643531... | lld:pubmed |
| pubmed-article:20643531 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20643531 | pubmed:articleTitle | Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy. | lld:pubmed |
| pubmed-article:20643531 | pubmed:affiliation | Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:20643531 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20643531 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:20643531 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:29527 | entrezgene:pubmed | pubmed-article:20643531 | lld:entrezgene |
